Quick Answer
Damora Therapeutics, Inc. reported Net Income of -$209.84 million for fiscal year 2025.
Damora Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$209.84M | -878.8% |
| 2024 | -$21.44M | +44.1% |
| 2023 | -$38.35M | +37.8% |
| 2022 | -$61.62M | -19.1% |
| 2021 | -$51.75M | -48.6% |
| 2020 | -$34.84M | +4.6% |
| 2019 | -$36.51M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.13M | +19.3% | +8.8% |
| June 30, 2025 | -$3.44M | +35.6% | -35.7% |
| March 31, 2025 | -$2.53M | +53.8% | +34.8% |
| September 30, 2024 | -$3.88M | +52.3% | +27.3% |
| June 30, 2024 | -$5.34M | +50.3% | +2.5% |
| March 31, 2024 | -$5.48M | +57.8% | +32.7% |
| September 30, 2023 | -$8.14M | +40.7% | +24.3% |
| June 30, 2023 | -$10.74M | +36.4% | +17.3% |
- Damora Therapeutics, Inc. showed a decrease of -878.8% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Damora Therapeutics, Inc.’s net income has declined by 474.8% (from -$36.51 million to -$209.84 million).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: